

Protokoltitel	NMDSG14B
Diagnose	MDS / mixed MDS/MPD / AML with multilinear dysplasia and <30% blasts
Protokolnummer	NMDSG14B
Danske centre	Rigshospitalet, Aarhus
Formål, design og resume	<ul style="list-style-type: none"> - To determine the predictive value, sensitivity and specificity of patient-specific molecular MRD markers for resistant disease and relapse in patients with MDS undergoing SCT. - To define cut-off values signalling impending relapse for the different mutations (e.g. different cut-offs for TP53 and TET2) - To evaluate the sensitivity of MRD from peripheral blood samples compared to bone marrow samples. - To determine the prognostic value of pre-treatment mutational profile for outcome after SCT. - To assess the efficacy of different pre-SCT treatments of reducing MRD levels before SCT. - To, during this clinical trial, collect a biobank of consecutive blood and bone marrow samples from each patient allowing for studies of stem/progenitor cells, microenvironment and immune system before and after transplantation with regard to genetic, epigenetic and immunological features.
Hvilke ptt.	MDS/mixed MDS/MPD/AML with multilinear dysplasia and <30% blasts scheduled for SCT
Hvor mange ptt.	300 i alt. Ca. 10-15 (RH) og 5-8 (Århus)
Hvordan	Når patienter henvises til transplantations afsnit med ovenstående diagnoser og der gives samtykke.
Hvor længe	Ca. 4 år (2020)
Særlige dosismodifikationer	N/A
Særlige in- eller eksklusions kriterier	N/A
Randomisering hvordan:	Ingen randomisering men registrering via fax til Karolinska University Hospital i Sverige.
Særlige KAT opgaver	Registrering af patienter, forsendelser af prøver
Andet	N/A
KAT ansvarlig pro. spl.	Navn: Marie-Thérèse Bejstrup Tlf. nr. 5-0508
Forsøgsansvarlig læge	Navn: Lone S. Friis Tlf. nr. 5-1757